Prelude Therapeutics (PRLD) Price & Analysis

Compare

167 Followers

PRLD Stock Chart & Stats

$1.63

-$0.05(-4.55%)

At close: Jan 08 4:00 PM EST

$1.63

-$0.05(-4.55%)

Day’s Range― - ―

52-Week Range$0.61 - $4.22

Previous CloseN/A

Volume107.75K

Average Volume (3M)256.05K

Market Cap

$99.61M

Enterprise Value$6.21M

Total Cash (Recent Filing)$54.96M

Total Debt (Recent Filing)$17.85M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Mar 18, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding43,744,064

10 Day Avg. Volume194,393

30 Day Avg. Volume256,051

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.73

Price to Sales (P/S)13.75

P/FCF Ratio-0.93

Enterprise Value/Market Cap0.06

Enterprise Value/Revenue0.59

Enterprise Value/Gross Profit0.62

Enterprise Value/Ebitda-0.05

Forecast

1Y Price Target

$5.00

Price Target Upside206.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPresentation of updated results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers is expected to be a catalyst.

Financial PositionThe cash position of $133.6 million provides a strong financial foundation for Prelude Therapeutics.

Market PotentialPrelude Therapeutics shares represent a unique investment opportunity, with a potential upside of 646%.

Bears Say

Clinical RisksRisks include negative clinical results for PRT3789 and delays in advancing these candidates into registrational programs.

Competitive RisksThe competitive landscape poses risks, particularly with respect to other SMARCA2 inhibitors/degraders that are currently in clinical development.

Prelude Therapeutics News

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

16:11 EST Prelude Therapeutics (PRLD) files to sell 6.25M shares of common stock for holders Published first on...

3d ago

PRLD

Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs

Prelude Therapeutics (PRLD) the first preclinical data on its JAK2V617F mutant selective JH2 inhibitors and additional preclinical data...

6d ago

PRLD

Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges

Prelude Therapeutics, Inc. (($PRLD)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

PRLD

Prelude Therapeutics Advances Pipeline and Strengthens Financials

Prelude Therapeutics, Inc. ( ($PRLD) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

PRLD

Prelude Therapeutics Reports Q3 2025 Financial Results

Prelude Therapeutics ( ($PRLD) ) has issued an update. Prelude Therapeutics reported its third-quarter 2025 financial results and...

1M ago

PRLD

Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year

Reports Q3 revenue $6.5M vs. $3M last year. “Last week, we announced a number of strategic updates that...

1M ago

PRLD

Prelude Therapeutics sees cash runway into 2027

At September 30, 2025, the Company had cash, cash equivalents, restricted cash and marketable securities totaling $58.2 million....

1M ago

PRLD

Is PRLD a Buy, Before Earnings?

Prelude Therapeutics, Inc. (PRLD) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

1M ago

PRLD

Prelude Therapeutics Signs Option Agreement with Incyte

Prelude Therapeutics ( ($PRLD) ) has provided an update. On November 3, 2025, Prelude Therapeutics entered into an...

1M ago

PRLD

Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?

Prelude Therapeutics stock fell on Tuesday after the company announced an exclusive options agreement. ...

1M ago

INCY

PRLD

Prelude Therapeutics announces exclusive option agreement with Incyte

Prelude Therapeutics (PRLD) announced an exclusive option agreement with Incyte (INCY) focused on Prelude’s previously undisclosed mutant selective...

1M ago

INCY

PRLD

Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs

Prelude Therapeutics (PRLD) is providing a number of strategic updates, including its recently executed option agreement with Incyte...

1M ago

INCY

PRLD

Prelude Therapeutics pauses development of SMARCA2 degrader program

Prelude announced it has decided to pause the clinical development of its SMARCA2 degrader program. The decision to...

1M ago

PRLD

Prelude Therapeutics sees cash runway into 2027

Based on these announcements, the Company’s cash runway is now expected to extend into 2027 based on the...

1M ago

PRLD

PRLD FAQ

What was Prelude Therapeutics’s price range in the past 12 months?

Prelude Therapeutics lowest stock price was $0.61 and its highest was $4.22 in the past 12 months.

What is Prelude Therapeutics’s market cap?

Prelude Therapeutics’s market cap is $99.61M.

When is Prelude Therapeutics’s upcoming earnings report date?

Prelude Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 94 days.

How were Prelude Therapeutics’s earnings last quarter?

Prelude Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.11.

Is Prelude Therapeutics overvalued?

According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prelude Therapeutics pay dividends?

Prelude Therapeutics does not currently pay dividends.

What is Prelude Therapeutics’s EPS estimate?

Prelude Therapeutics’s EPS estimate is -0.13.

How many shares outstanding does Prelude Therapeutics have?

Prelude Therapeutics has 43,744,064 shares outstanding.

What happened to Prelude Therapeutics’s price movement after its last earnings report?

Prelude Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 8.889%.

Which hedge fund is a major shareholder of Prelude Therapeutics?

Currently, no hedge funds are holding shares in PRLD

Prelude Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-103.99%

Trailing 12-Months

Asset Growth

-48.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prelude Therapeutics

Prelude Therapeutics (PRLD) is a biopharmaceutical company dedicated to the discovery and development of innovative cancer therapies. The company focuses on creating small-molecule therapies that target key drivers of cancer cell growth, survival, and resistance. Prelude Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in oncology through its research and development efforts.

Prelude Therapeutics (PRLD) Earnings & Revenues

Historic Earnings Reports

PRLD Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.View all PRLD earnings summaries

PRLD Stock 12 Month Forecast

Average Price Target

$5.00

▲(206.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.4276923076923076,1.7253846153846153,2.023076923076923,2.3207692307692307,2.6184615384615384,2.916153846153846,3.213846153846154,3.5115384615384615,3.809230769230769,4.106923076923077,4.404615384615385,4.702307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.4276923076923076,1.7253846153846153,2.023076923076923,2.3207692307692307,2.6184615384615384,2.916153846153846,3.213846153846154,3.5115384615384615,3.809230769230769,4.106923076923077,4.404615384615385,4.702307692307692,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.4276923076923076,1.7253846153846153,2.023076923076923,2.3207692307692307,2.6184615384615384,2.916153846153846,3.213846153846154,3.5115384615384615,3.809230769230769,4.106923076923077,4.404615384615385,4.702307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.73,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >